Member Info for flyingmachine

......does that include litigation costs against the hospital when parents find out the profound deafness was caused by gentamicin antibiotics, which could have been avoided by using an available AIHL test from Genedrive!

I think the AIHL test salesman/distributor is going to have it easy with AIHL tests in the US!

BigAl67, I think the number is potential 180 neonates (newborns) annually within the UK will avoid antibiotic induced hearing loss. That's testing about 90000 babies every year in the UK who end up in ICU and need antibiotics. That saves 180 cochlear implants each year at a cost of £50k per implant, so the NHS saves money overall. Not to mention the positive impact to the lives of those children and their families. This will take off in the USA and Europe too as well as elsewher in the world. Everybody wins, including Genedrive shareholders!

DD77, the AIHL test will save health care costs - every baby that loses their hearing due to antibiotics needs a cochlear impart. In the UK that costs £50k. I remember reading that the NHS has already calculated a net saving by having this test. Overall, there is a saving to health care costs even when every ICU baby is tested. So take up will be supportd by costs savings as well as the enormous benefit of avoiding hearing loss in newborns.

Groover, well said. I am sticking with my investment. I am confident of what's coming along soon and it's not all about Covid.

Recommend investors to attend. There is potential for a lot of positive news to land very soon, so worth a listen in.

Investor presentation on InvestorMeet at 10.00am on Wednesday 18th November.

BTW, it is normal for a company to be asked not to release any numerical data from a study until its conclusion so don't be surprised if they cannot echo the data from the tweet, even if it is now in the public domain from a different source.

I know that the trial will definitely end November 30th (no further extension as recruitment into the trial will be adequate), then I hope to see the NIHR PALOH trial report in early 2021 followed swiftly by formal launch by Genedrive within the UK and abroad.........£40m-£64m annual earnings expectation from this test, so even more of a bargain after today!

PALOH - Pharmacogenetics to avoid loss of hearing. This is the acronym for the Genedrive AIHL trial in liverpool and Manchester.

Twitter update from November 6.....

https://twitter.com/Ddysmo/status/1324723050013741058

Two babies already saved from profound deafness during the AIHL trial in Liverpool and Manchester (target 900 neonate participants in trial, 1 in 500 are affected by gentamicin antibiotics, so matches expectations). Also, the Gene panel, THE GENEDRIVE panel, in development for other medicine risks!!! The trial ends 30th November, so not long before formal launch.

we should see sales of AIHL tests progressing quickly after formal launch. Its a no-brainer for maternity units all over the world to use these tests, it is life changing and saves health costs as well....

https://www.independent.co.uk/news/health/baby-deafness-gentamacin-test-genedrive-neonatal-care-nhs-a9294411.html

Genedrive expecting £40m-£65m earnings annually from this test alone, nearly twice as current Mcap (£34m)! This will drive strong growth from this very bargain basement SP level!

Genedrive is not simply just a Covid play, remember this!

It's good to see some focus now on the AIHL test and other non-covid tests in the Genedrive locker. I still expect the Covid testing to become good but it was an easy target to shoot down with the delay in the approvals. No matter, Covid or not, a successful AIHL launch and HCV sales, as well as USA DoD sales will provide a foundation for strong growth from these low levels.

It is exciting Dartron, so much to look forward to with updates for Gendrives AIHL and HCV product lines. If anything good happens with the Covid tests, excellent, that will just be icing on the cake!

...yes, we should see sales of AIHL tests progressing quickly after formal launch. Its a no-brainer for maternity units all over the world to use these tests, it is life changing and saves health costs as well....

https://www.independent.co.uk/news/health/baby-deafness-gentamacin-test-genedrive-neonatal-care-nhs-a9294411.html

Genedrive expecting £40m-£65m earnings annually from this test alone, nearly twice as current Mcap!

very transparent dreamachine, you are getting to sound desparate for your trades :-)

...and for anyone who missed this press report the first time round and how significant this test is -

https://www.independent.co.uk/news/health/baby-deafness-gentamacin-test-genedrive-neonatal-care-nhs-a9294411.html

Liverpool and Manchester trials to be ending soon.

grimshady, yes agreed, those are the HCV test sales I mentioned.....keys in the ignition....

I believe we are at the point now where we have two potential catalysts to SP growth - Covid testing and AIHL.

I expect news next week that formal AIHL test launch will be coming in a few weeks. If you do not know what the AIHL test is all about, then go and do some more research. Then ask yourself the question why hospitals will not rapidly be taking up the AIHL test across the UK, Europe and USA. It even saves money for health services - cochlear implants cost £50k, the AIHL test avoids this cost and has such a fantastic positive life-changing impact to newborns and their families.

Expected Market is at least 90k tests/year in just the UK, the USA and Europe market are each 5 times bigger. Genedrive anticipate earnings from this test to amount to £40-£65m per year. So earnings per year for Genedrive from the AIHL test could be nearly twice today's Mcap. Just on AIHL test alone the Mcap can go many multiples of where the SP is now.
I believe the annual earnings from just the UK alone supports the current Gendrive Mcap. This is without any impact from AIHL sales from Europe and USA nor any future HCV and USA DoD test sales, and absolutely no reliance on Covid sales. Covid sales will be icing on the cake for Genedrive but Genedrive is not reliant on Covid sales to drive company growth.

Keys are in the ignition for AIHL.....

ditto, meaning attend the presentation next week and then crunch the numbers around AIHL....

LP160606, ditto.....

ThePunter1, be sure to attend the update next week, and then crunch the numbers.....

.....bumping this again as I believe we are at the point now where we have two potential catalysts to SP growth - Covid testing and AIHL. So much talk still by some folks saying we have missed the boat on covid testing, maybe or maybe not. Well, if we have missed the covid boat (but I don't think we have) we should not be forgetting the AIHL tests which is the other 'engine' to Genedrive growth, the keys are in the ignition.

I expect news next week that formal AIHL test launch will be coming in a few weeks. If you do not know what the AIHL test is all about, then go and do some more research. Then ask yourself the question why hospitals will not be using this test across the UK, Europe and USA. Then check the potential earning per year for the company that AIHL tests will bring and compare it with todays MCap. This company is not simply reliant on Covid tests to propel its growth.